UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/580,646	02/06/2007	Ivo Glynne Gut	065691-0447	5348
	7590 10/15/200 LARDNER LLP	EXAMINER		
SUITE 500	T NIXI	CALAMITA, HEATHER		
3000 K STREET NW WASHINGTON, DC 20007			ART UNIT	PAPER NUMBER
			1637	
			MAIL DATE	DELIVERY MODE
			10/15/2009	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	Application No.	Applicant(s)			
	10/580,646	GUT ET AL.			
Office Action Summary	Examiner	Art Unit			
	HEATHER G. CALAMITA	1637			
The MAILING DATE of this communication app Period for Reply	ears on the cover sheet with the c	orrespondence address			
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING DA - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period w - Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be tim vill apply and will expire SIX (6) MONTHS from cause the application to become ABANDONE	N. nely filed the mailing date of this communication. D (35 U.S.C. § 133).			
Status					
1) ☐ Responsive to communication(s) filed on 27 Ju 2a) ☐ This action is FINAL . 2b) ☐ This 3) ☐ Since this application is in condition for allowant closed in accordance with the practice under E	action is non-final. nce except for formal matters, pro				
Disposition of Claims					
4) Claim(s) 1-7,9,13 and 18-21 is/are pending in the 4a) Of the above claim(s) 18 is/are withdrawn from 5) Claim(s) 1-7 and 19-21 is/are allowed. 6) Claim(s) 9 and 13 is/are rejected. 7) Claim(s) is/are objected to. 8) Claim(s) are subject to restriction and/or are subject to restriction and/or are subject to by the Examine 10) The drawing(s) filed on is/are: a) access	rom consideration. election requirement.	-vaminor			
Applicant may not request that any objection to the or Replacement drawing sheet(s) including the correction to the orange of the oath or declaration is objected to by the Example 11).	drawing(s) be held in abeyance. See on is required if the drawing(s) is obj	e 37 CFR 1.85(a). jected to. See 37 CFR 1.121(d).			
Priority under 35 U.S.C. § 119					
 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 					
Attachment(s) 1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date 5/25/2006.	4) Interview Summary Paper No(s)/Mail Da 5) Notice of Informal P 6) Other:	ate			

Application/Control Number: 10/580,646 Page 2

Art Unit: 1637

DETAILED ACTION

Election/Restrictions

1. To clarify the record the Restriction requirement mailed May 27, 2009, contained two typographical errors. The Groups in the restrictions referred to the correct claims, however the inventions were not correctly characterized. The invention of Group I (claims 1-17 and 19-21) is drawn to a method of HLA typing. The invention of Group II (claim 18) is drawn to a kit for use in HLA typing.

2. Applicants' election with traverse of Group I (claims 1-17 and 19-21) and the species of HLA-A and the subspecies of HLA-A in the reply filed on July 27, 2009, is acknowledged. The traversal is on the ground(s) that a special technical feature exists. This is not found persuasive because as outlined in the requirement mailed May 27, 2009, there is no special technical feature because the components disclosed in the kit are known in the prior art.

The requirement is still deemed proper and is therefore made *FINAL*.

Status of Application, Amendments, and/or Claims

3. Claims 1-7, 9, 13 and 18-21 are currently pending. Claim 18 is withdrawn as being directed to non-elected subject matter. Claims 1-7, 9, 13 and 19-21 are under examination.

Information Disclosure Statement

4. The information disclosure statement filed May 25, 2006, fails to comply with 37 CFR 1.98(a)(2), which requires a legible copy of each cited foreign patent document; each non-patent literature publication or that portion which caused it to be listed; and all other information or that portion which caused it to be listed. It has been placed in the application file, but the information referred to therein has

Art Unit: 1637

not been considered. The lined through references have not been considered because no copy of the reference was provided.

Claim Rejections - 35 USC § 112

5. The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claims 9 and 13 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Claims 9 and 13 both depend from claim 1. Claim 1 is drawn to a method of HLA-A typing to generate subgroups A to O by determination f DNA sequence elements on both parental alleles at a set of multiple positions in the HLA-A gene. The set *consists* of 10 positions. Claim 9 requires 9 additional positions and claim 13 requires 25 additional positions. Claims 9 and 13 do not properly depend from claim 1 because claim 1 uses the language of *consists of* when defining the set. The language allows for only the 10 positions recited in claim 1 and not for the additional positions recited in claims 9 and 13.

Allowable Subject Matter

6. Claims 1-7 and 19-21 are allowed. The closest prior art is Warrell et al. (Analytical Chemistry vol. 72:5233-5238 2000) and Rozemuller ("Reference panels for sequence based typing: Selection criteria for HLA-A and HLA-B", Technical Manuel International Histocompatibility Working Group, 2000). Warrell et al. teach a method for HLA typing by mass spectrometry. Warrell et al. use primer oligomer base extension combined with matrix-assisted laser desorption/ionization tome of flight mass spectrometry to characterize HLA polymorphisms in both parental alleles. Rozemuller teach the polymorphic positions in HLA-A and HLA-B. However, even though HLA typing is well known in the

Application/Control Number: 10/580,646 Page 4

Art Unit: 1637

art and the polymorphic positions are disclosed by Rozemuller it is not obvious to use the specific combinations of positions recited for the typing of HLA-A. There is no reason or motivation provided for a skilled artisan to choose one specific subset of 10 positions over any other specific subset of 10 positions.

Correspondence

7. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Heather G. Calamita whose telephone number is 571.272.2876 and whose e-mail address is heather.calamita@uspto.gov. However, the office cannot guarantee security through the e-mail system nor should official papers be transmitted through this route. The examiner can normally be reached on Monday through Thursday, 7:00 AM to 5:30 PM.

If attempts to reach the examiner are unsuccessful, the examiner's supervisor, Gary Benzion can be reached at 571.272.0782.

Papers related to this application may be faxed to Group 1637 via the PTO Fax Center using the fax number 571.273.8300.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to 571.272.0547.

Patent applicants with problems or questions regarding electronic images that can be viewed in the Patent Application Information Retrieval system (PAIR) can now contact the USPTO's Patent Electronic Business Center (Patent EBC) for assistance. Representatives are available to answer your questions daily from 6 am to midnight (EST). The toll free number is (866) 217-9197. When calling please have your application serial or patent number, the type of document you are having an image problem with, the number of pages and the specific nature of the problem. The Patent Electronic Business Center will notify applicants of the resolution of the problem within 5-7 business days. Applicants can also check PAIR to confirm that the problem has been corrected. The USPTO's Patent Electronic Business Center is a complete service center supporting all patent business on the Internet. The USPTO's PAIR system provides Internet-based access to patent application status and history information. It also enables applicants to view the scanned images of their own application file folder(s) as well as general patent information available to the public. For more information about the PAIR system, see http://pair-direct.uspto.gov.

For all other customer support, please call the USPTO Call Center (UCC) at 800-786-9199.

/Heather G. Calamita/ Examiner, Art Unit 1637